Wednesday, April 30th, 2025

Unlocking Growth: Pavilion REIT’s Promising Outlook Amidst Market Challenges

Date of Report

25 October 2024

Broker Name

UOB Kay Hian

Company Overview

Pavilion REIT is a real estate investment trust (REIT) with a portfolio that includes the iconic Pavilion Shopping Mall and the Pavilion Office Tower.

Stock Data

  • Share Price: RM1.58
  • Target Price: RM1.76 (Previous TP: RM1.66)
  • Upside: +11.4%
  • Bloomberg Ticker: PREIT MK
  • Shares Issued: 3,660.7 million
  • Market Cap: RM5,756.2 million (US$1,335.5 million)
  • 3-Month Average Daily Turnover: US$1.5 million
  • 52-Week High/Low: RM1.59 / RM1.17

Major Shareholders

  • Qatar Investment Authority: 27.6%
  • Lim Siew Choon: 23.1%
  • Employees Provident Fund: 12.1%

Financial Performance

3Q24 Results

  • Revenue: RM207.3 million (+3% QoQ, +4% YoY)
  • Net Property Income (NPI): RM131.9 million (+9.8% QoQ, +8.7% YoY)
  • Core PAT: RM78.9 million (+17.6% QoQ, +11.8% YoY)
  • Earnings Per Unit (EPU): 2.2 sen
  • Dividend Per Unit (DPU): 0.0 sen (no dividend declared for this quarter)

Key Financials (Year to 31 Dec)

Metric 2022 2023 2024F 2025F 2026F
Net Turnover (RMm) 570 724 835 873 902
EBITDA (RMm) 332 419 467 496 512
Net Profit (RMm) 398 432 320 352 370
EPU (sen) 8.1 8.4 8.8 9.6 10.1
DPU (sen) 8.4 9.0 9.0 9.6 10.0

Stock Impact

  • The results for 3Q24 were slightly below expectations due to weaker-than-expected performance from Pavilion Bukit Jalil (PBJ), which may miss its RM146 million NPI target for next year.
  • The 3Q24 NPI margin improved to 63.6%, driven by higher margins from key assets like Pavilion KL, Pavilion Elite, and Intermark Mall.
  • A stronger fourth quarter is anticipated due to the festive season, with occupancy at Pavilion KL remaining solid at 96.8%.

Earnings Revision/Risk

  • Earnings forecasts for 2024-26 have been reduced by 2-6% due to lower expected contributions from PBJ.
  • The expectation of a dilutive RM400 million placement exercise in 2025 has been removed, leading to an increase in DPU forecasts by 4-6% for 2025-26.

Valuation/Recommendation

  • Maintain a “BUY” rating with a higher target price of RM1.76, based on an increased dividend forecast and a reasonable implied dividend yield of 5.5% for 2025.

V.S. Industry: Strong Growth Outlook with New Customer Orders and Expansion Plans

V.S. Industry: A Comprehensive Analysis of Future Prospects and Financial Performance Date: December 9, 2024 Broker: Maybank Investment Bank Berhad Introduction V.S. Industry Berhad (VSI) is an established player in the electronics manufacturing services...

CapitaLand Integrated Commercial Trust: Dominating Singapore’s Retail Scene

CapitaLand Integrated Commercial Trust: Dominating Singapore’s Retail Scene UOB Kay Hian, October 4, 2024 CapitaLand Integrated Commercial Trust (CICT) is solidifying its position as a dominant force in Singapore’s retail market. With strategic acquisitions...

Sino Biopharmaceutical Ltd Positioned for Strong Gains with Technical Buy Momentum

Date: September 17, 2024Broker: CGS-CIMB Securities Company Overview Sino Biopharmaceutical Ltd (Stock Code: 1177) is a major pharmaceutical company based in Hong Kong. It focuses on the research, development, production, and distribution of biopharmaceutical...